Key Highlights

  • CMS 2027 Star Ratings lifted Humana's (NYSE:HUM) biggest Medicare Advantage contract to 4 stars from 3.5, a change that can raise federal Bonus payments, announced after the close on October 8, 2026, with the largest contract affecting many members.
  • Humana (NYSE:HUM) rose 12% after hours and about 14.95% premarket to 445, while another summary shows 16.5%, a conflict that has not been reconciled and may reflect different quote times.
  • Alignment Healthcare (NASDAQ:ALHC) fell about 23% to 24% after its California contract, which covers about 81% of its membership, was cut to 3.5 stars from 4, a concentrated exposure.
  • Baird upgraded Humana (NYSE:HUM) to Outperform with a USD 596 target, a call that adds analyst support to the ratings result and signals that Wall Street sees Earnings upside.

The Ratings Result

The Centers for Medicare and Medicaid Services released its 2027 Star Ratings after the close on October 8, 2026. The ratings grade Medicare Advantage plans on quality and service from one to five stars, and plans rated 4 or higher qualify for quality bonus payments that fund richer benefits. Humana's largest contract moved to 4 stars from 3.5, which could restore bonus eligibility for a large share of its members. Alignment Healthcare's California contract, which holds about 81% of its membership, fell to 3.5 stars from 4. Because bonus payments depend on the rating, one half-star can change Revenue for many members at once. The ratings affect the plan year that follows, not the one in progress.

How the Stocks Reacted

The reaction was large and uneven. Humana (NYSE:HUM) rose about 12% after hours in one account, and about 14.95% premarket to USD 445, while a separate summary reports a 16.5% gain. These figures come from different times and are unreconciled, so the regular-session open should be checked. Alignment (NASDAQ:ALHC) dropped about 23% to 24% since a single contract carries most of its membership, so the rating hits a larger share of revenue than it would at a diversified insurer. Baird upgraded Humana to Outperform with a USD 596 target, which would imply upside from the premarket quote, simple arithmetic on two published numbers, about 34% above the quote. That upside is an analyst view, not a forecast we endorse.

Risks and What to Watch

Star Ratings are only one input. Medical costs, government rate notices and utilization trends also shape Medicare Advantage margins, and Humana (NYSE:HUM) still faces cost pressure from seniors using more services. Ratings can also be reviewed or appealed, and bonus payments arrive with a lag, so the revenue effect builds over time. For Alignment, the question is whether it can recover its California rating and retain members. Watch for company statements, appeals, open enrollment commentary in the fall, and the first full session of trading after the release. Peer insurers may also move as investors reassess ratings across the industry. The premarket quotes are not timestamped, so the open may look different.

Where Things Stand

Humana surged because a higher rating on its biggest Medicare Advantage contract can bring bonus payments and membership gains, while Alignment fell because a lower rating on its California contract hits most of its members. Humana (NYSE:HUM) now has analyst support from Baird, but the size of the move varies from 12% to 16.5% by data provider. The rating is a binary regulatory result with real financial impact, though costs and enrollment still matter. Recheck prices at the open.